Overview of Antibody-Drug Conjugates (ADCs) with a retrospective analysis of regulatory filing data, focusing on genotoxicity, hERG liability, and phototoxicity. It will cover key considerations for genetic toxicology testing in ADCs, including the genotoxic mechanisms of payloads. Additionally, the session will address best practices for hERG assessments, highlighting regulatory expectations and strategies to evaluate cardiac safety risks in ADC development.